icon
沙特阿拉伯王国政府所属的官方政府网站。
icon 周四 25 6月 2026
icon
沙特官方政府网站的域名以下列后缀结尾 gov.sa

沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。

icon
政府网站使用以下协议。 HTTPS 用于加密和安全。

沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。

icon
在数字政府管理局注册,编号:
20250831619
建议

Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Diatab tablets (5 mg glibenclamide) Produced by SPIMACO / KSA versus Daonil® tablets (5 mg glibenclamide) Produced by Sanofi- Aventis / Germany, in healthy subjects under fed condition.

Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Diatab tablets (5 mg glibenclamide) Produced by SPIMACO / KSA versus Daonil® tablets (5 mg glibenclamide) Produced by Sanofi- Aventis / Germany, in healthy subjects under fed condition.

icon 2020-07-04
عنوان الدراسة
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Diatab tablets (5 mg glibenclamide) Produced by SPIMACO / KSA versus Daonil® tablets (5 mg glibenclamide) Produced by Sanofi- Aventis / Germany, in healthy subjects under fed condition.
داعم الدراسة
SFDA
دواء الدراسة
Diatab
رقم بروتوكول الدراسة
18-2017
حالة الدراسة
Ongoing
موقع الدراسة
Saudi Ajal
مرحلة الدراسة
BE